JPRN-UMIN000015971
Completed
Phase 2
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. - A phase II study of Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.
Sairtama Breast Cancer Clinical Study Group (SBCCSG)0 sites51 target enrollmentJanuary 1, 2015
ConditionsHER2-negative metastatic breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HER2-negative metastatic breast cancer
- Sponsor
- Sairtama Breast Cancer Clinical Study Group (SBCCSG)
- Enrollment
- 51
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)having systemic infection with a fever of 38 degrees or more 2\)protocol treatment of drug, and a history of hypersensitivity to the solvent 3\)patients with brain metastases in need of treatment to the brain hypertension and emergency brain radiation 4\)patients with following serious complication ischaemic heart disease or heart disease such as arrhythmia not controllable by treatment myocardial infarction \< 6 months prior to study entry hepatic cirrhosis interstitial pneumonia or pulmonary fibrosis bleeding tendency Uncontrolable hypertension Uncontrolable proteinuria 5\)having active double cancer 6\)patients with a history of radiation therapy to the measurable lesions 7\)history of mental disorder, a central nervous system damage, and cerebral blood vessel neuropathy 8\)pregnancy, breast\-feeding or women with childbearing potential 9\)patients undergoing continuous systemic administration of steroids 10\)HBs antigen is positive 11\)judged by the investigator not to be appropriate for the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28)advanced or recurrent breast cancerJPRN-UMIN000009090Saitama Breast Cancer Clinical Study Group (SBCCSG)70
Completed
Phase 2
Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung canceron-small-cell lung cancerJPRN-UMIN000004573First Department of Internal Medicine, Shinshu University School of Medicine42
Recruiting
Phase 2
A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapyarge cell neuroendocrine carcinoma (LCNEC)JPRN-UMIN000011713Toho University Omori Medical Center19
Active, not recruiting
Not Applicable
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-000802-30-ITROCHE
Active, not recruiting
Not Applicable
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE